Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking approach to diabetes management. These innovative therapies operate by mimicking the physiological actions of GLP-1, a hormone secreted by the gut in response to food. By triggering GLP-1 receptors in the pancreas, these substances increase insulin production and inhibi

The management of diabetes is with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant traction. These medications offer promising mechanisms for controlling blood sugar levels and may improve the lives of individuals living with diabetes. This novel class of dr